zeleciment rostudirsen
z-rostudirsen · DYNE-251 Nucleic Acid Target: TfR1, dystrophin exon 51, dystrophin, exon 51
Dyne Therapeutics
Most recent annual filing: 2026-03-02
- DYNE-302 Ph1 readout2H 2026DYNE-302 Ph1 readout, 2H 2026, routine
- z-basivarsen pivotal topline1Q 2027z-basivarsen pivotal topline, 1Q 2027, material
- z-rostudirsen FDA decisionJan 21, 2027z-rostudirsen FDA decision, Jan 21, 2027, major
- Hercules covenant FDA approvalOct 2027Hercules covenant FDA approval, Oct 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (10 active programs)
zeleciment basivarsen
z-basivarsen · DYNE-101 Nucleic Acid Target: TfR1, DMPK, DMPK RNA
DYNE-302
Nucleic Acid Target: TfR1, DUX4
DYNE-401
DYNE-253
Nucleic Acid Target: TfR1, dystrophin exon 53, exon 53
DYNE-245
Nucleic Acid Target: TfR1, dystrophin exon 45, exon 45
DYNE-244
Nucleic Acid Target: TfR1, dystrophin exon 44, exon 44
DYNE-255
Nucleic Acid Target: TfR1, dystrophin exon 55, exon 55
Conjugate 1
Nucleic Acid Target: MAPT
- Undisclosed indication
Conjugate 2
Nucleic Acid Target: MAPT
- Undisclosed indication
Technology platforms
FORCE
TfR1-targeting Fab-conjugate delivery platform that links therapeutic payloads (PMOs, ASOs, siRNAs, enzymes) to a proprietary anti-TfR1 Fab via a clinically-validated linker, enabling targeted delivery to skeletal, cardiac and smooth muscle and CNS. Disease focus: neuromuscular diseases including DMD, DM1, FSHD, Pompe disease, rare skeletal muscle diseases, and cardiac/metabolic muscle diseases.
Targets: TfR1, transferrin receptor 1
Biotech Distilled coverage (12)
- 2026-07-30 UPDATE: Dyne Therapeutics (DYN) - The Q2 Print and Two Buried Footnotes 🔒 Paid
- 2026-07-28 UPDATE: Dyne Therapeutics (DYN) - The Third Package 🔒 Paid
- 2026-07-22 UPDATE: Dyne Therapeutics (DYN) - The Raise Prices 🔒 Paid
- 2026-07-21 UPDATE: Dyne Therapeutics (DYN) - The Day-After Raise 🔒 Paid
- 2026-07-20 UPDATE: Dyne Therapeutics (DYN) - The PDUFA Clock is Set 🔒 Paid
- 2026-06-17 UPDATE: Dyne Therapeutics (DYN) - The Non-Dilutive Top-Off
- 2026-06-03 UPDATE: Dyne Therapeutics (DYN) - The Second Catalyst Lands
- 2026-05-26 UPDATE: Dyne Therapeutics (DYN) - The BLA is In 🔒 Paid
- 2026-03-14 UPDATE: Dyne Therapeutics (DYN) - Generational Moment 🔒 Paid
- 2026-03-07 UPDATE: Dyne Therapeutics (DYN) - Annual Audit 🔒 Paid
- 2026-01-22 UPDATE: Dyne Secures Japan Orphan Drug Designation (ODD) 🔒 Paid
- 2026-01-20 Dyne Therapeutics (DYN): Scientific Due Diligence for FORCE™ and Pipeline Products 🔒 Paid
Articles open on Substack. Some deep dives are subscriber-only.